tumor necrosis factor-related apoptosis-inducing ligand / DR4 Cancer Research Results

TRAIL/rTRAIL, tumor necrosis factor-related apoptosis-inducing ligand: Click to Expand ⟱
Features:

Recombinant TRAIL - Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

Recommended Abbreviation: rTRAIL

Alternative Names: Recombinant TRAIL, recombinant TNFSF10, Apo2L/TRAIL

Type: Recombinant protein / biologic anticancer agent / death-receptor agonist

Function: Recombinant TRAIL binds primarily to the death receptors DR4 (TNFRSF10A) and DR5 (TNFRSF10B), causing death-inducing signaling complex formation, caspase-8 activation, downstream caspase activation, and apoptosis. Many cancer cells are more sensitive to TRAIL-induced apoptosis than normal cells, although resistance is common.

Cancer: ↑ TRAIL-induced death-receptor signaling is generally favorable because it promotes extrinsic apoptosis in susceptible cancer cells. Recombinant TRAIL and TRAIL-receptor agonists have shown substantial preclinical anticancer activity, although clinical efficacy has been limited by short circulating half-life, receptor biology, and intrinsic or acquired TRAIL resistance.
DR4, Death Receptor 4: Click to Expand ⟱
Source:
Type: protein
DR4 (Death Receptor 4, also known as TRAIL receptor 1 or TNFRSF10A).
DR4 is one of the main receptors for TRAIL (TNF-related apoptosis-inducing ligand). • Upon TRAIL binding, DR4 can trigger the extrinsic apoptotic pathway, leading to caspase activation and programmed cell death.

Lower receptor levels often correlate with therapy resistance and aggressive tumor phenotypes, while appropriate or higher levels may enhance susceptibility to apoptosis-based therapies.
Scientific Papers found: Click to Expand⟱
8068- KAE,  TRAIL/rTRAIL,    Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis
- in-vitro, Colon, NA
eff↑, DR4↑, DR5↑,
8152- lamb,  TRAIL/rTRAIL,    Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4
- in-vitro, NSCLC, A549 - in-vitro, Lung, H1299
TumCD↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓, cFLIP↓, XIAP↓, BID↑, DR4↑, p‑NF-kB↓, p‑IκB↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

XIAP↓, 1,  

Cell Death(tgid=5) ⓘ

Bcl-2↓, 1,   BID↑, 1,   Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   cFLIP↓, 1,   DR4↑, 2,   DR5↑, 1,   TumCD↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

p‑IκB↓, 1,   p‑NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: DR4, Death Receptor 4
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:474  Target#:806  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page